Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 study of IFx-Hu2.0 first line therapy of patients with advanced Merkel cell carcinoma in sequence with pembrolizumab

Next Previous
Search
Trial Profile

A phase 3 study of IFx-Hu2.0 first line therapy of patients with advanced Merkel cell carcinoma in sequence with pembrolizumab

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 08 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IFx 2.0 (Primary) ; Pembrolizumab (Primary)
  • Indications Merkel cell carcinoma
  • Focus Adverse reactions; Registrational; Therapeutic Use

    • Most Recent Events

    • 01 Apr 2025 According to TuHURA Biosciences media release, this trial is planned to initiate enrollment in Q2 2025
    • 17 Oct 2024 According to a TuHURA Biosciences media release, company announced merger with Kintara Therapeutics, Inc. and the combined company will operate under the name "TuHURA Biosciences, Inc.''
    • 17 Oct 2024 According to TuHURA Biosciences media release, The Company is preparing to initiate a single Phase 3 accelerated approval registration trial in the first half of 2025 for treatment of 1st line Merkel Cell carcinoma under SPA agreement with FDA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top